| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $7,631,469 | 7 | 100 |
Sells | $0 | 0 | 0 |
| STAHLBERG JAN | 10 percent owner | 7 | $7.63M | 0 | $0 | $7.63M |
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is …
Over the last 12 months, insiders at DiaMedica Therapeutics Inc. have bought $7.63M and sold $0 worth of DiaMedica Therapeutics Inc. stock.
On average, over the past 5 years, insiders at DiaMedica Therapeutics Inc. have bought $9.39M and sold $3.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: STAHLBERG JAN (10 percent owner) — $7.63M.
The last purchase of 73,099 shares for transaction amount of $626,817 was made by STAHLBERG JAN (10 percent owner) on 2025‑11‑25.
| 2025-11-25 | STAHLBERG JAN | 10 percent owner | 73,099 0.1577% | $8.57 | $626,817 | -20.04% | ||
| 2025-11-24 | STAHLBERG JAN | 10 percent owner | 40,253 0.08% | $7.89 | $317,721 | -9.63% | ||
| 2025-11-21 | STAHLBERG JAN | 10 percent owner | 208,872 0.3895% | $7.41 | $1.55M | -5.11% | ||
| 2025-11-20 | STAHLBERG JAN | 10 percent owner | 128,426 0.253% | $7.41 | $951,213 | +0.42% | ||
| 2025-11-19 | STAHLBERG JAN | 10 percent owner | 240,352 0.4557% | $7.21 | $1.73M | -0.82% | ||
| 2025-11-18 | STAHLBERG JAN | 10 percent owner | 182,882 0.3436% | $6.75 | $1.23M | +5.07% | ||
| 2025-11-17 | STAHLBERG JAN | 10 percent owner | 187,393 0.3658% | $6.52 | $1.22M | +12.95% | ||
| 2025-08-27 | STAHLBERG JAN | 10 percent owner | 50,772 0.0986% | $6.00 | $304,632 | +14.88% | ||
| 2025-08-26 | STAHLBERG JAN | 10 percent owner | 59,648 0.1133% | $6.00 | $357,888 | +13.55% | ||
| 2025-08-25 | STAHLBERG JAN | 10 percent owner | 338,265 0.6425% | $6.00 | $2.03M | +14.50% | ||
| 2025-08-22 | STAHLBERG JAN | 10 percent owner | 59,788 0.1129% | $5.96 | $356,576 | +12.44% | ||
| 2025-08-21 | STAHLBERG JAN | 10 percent owner | 48,172 0.0936% | $5.96 | $287,028 | +15.85% | ||
| 2025-08-20 | STAHLBERG JAN | 10 percent owner | 71,107 0.1343% | $5.86 | $416,495 | +14.50% | ||
| 2025-08-15 | STAHLBERG JAN | 10 percent owner | 8,233 0.0158% | $6.00 | $49,398 | +13.93% | ||
| 2025-08-14 | STAHLBERG JAN | 10 percent owner | 70,414 0.1358% | $5.99 | $421,921 | +14.31% | ||
| 2025-08-13 | STAHLBERG JAN | 10 percent owner | 293,601 0.5594% | $5.91 | $1.73M | +14.50% | ||
| 2025-07-23 | Von Koch Thomas | 10 percent owner | 2.86M 4.528% | $3.50 | $10M | +33.20% | ||
| 2025-07-23 | STAHLBERG JAN | 10 percent owner | 1.54M 2.4451% | $3.50 | $5.4M | +33.20% | ||
| 2025-07-23 | JACINTO RICHARD II | 10 percent owner | 400,000 0.6339% | $3.50 | $1.4M | +33.20% | ||
| 2024-06-28 | Von Koch Thomas | 10 percent owner | 1.2M 2.6697% | $2.50 | $3M | +42.37% |
| STAHLBERG JAN | 10 percent owner | 8825742 16.3665% | $88.26M | 18 | 0 | +18.55% |
| Von Koch Thomas | 10 percent owner | 8383577 15.5465% | $83.84M | 4 | 1 | +22.59% |
| JACINTO RICHARD II | 10 percent owner | 4958823 9.1957% | $49.59M | 1 | 0 | +33.2% |
| TomEnterprise AB | 2855827 5.2959% | $28.56M | 1 | 0 | +16.67% | |
| Wambeke David J. | Chief Business Officer | 527114 0.9775% | $5.27M | 3 | 0 | +24.24% |
| Giuffre Randall Michael | director | 360355 0.6682% | $3.6M | 10 | 0 | +49.69% |
| Pilnik Richard D. | director | 248245 0.4603% | $2.48M | 7 | 0 | +16.82% |
| Pauls Dietrich John | President and CEO | 68591 0.1272% | $685,910.00 | 5 | 0 | +14.27% |
| Burroughs Amy L. | director | 44950 0.0834% | $449,500.00 | 1 | 0 | <0.0001% |
| ALCORN HARRY W JR | SVP, Clinical Operations | 43582 0.0808% | $435,820.00 | 5 | 0 | <0.0001% |
| Kellen Scott | CFO and Secretary | 32290 0.0599% | $322,900.00 | 6 | 0 | +15.37% |
| Semba Charles Pauling | director | 29943 0.0555% | $299,430.00 | 1 | 0 | <0.0001% |
| Xiao Zhenyu | 7100 0.0132% | $71,000.00 | 1 | 0 | <0.0001% | |
| Parsons James T. | director | 6100 0.0113% | $61,000.00 | 1 | 0 | <0.0001% |
| Verdoorn Todd A. | Chief Scientific Officer | 2000 0.0037% | $20,000.00 | 1 | 0 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
DiaMedica Therapeutics Inc. (DMAC) | $40,226,318 | 58 | 18.89% | $539.26M |
$16,169,789 | 40 | 7.44% | $485.1M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$8,866,498 | 28 | 33.64% | $474.26M |
| Increased Positions | 56 | +81.16% | 2M | +13.01% |
| Decreased Positions | 26 | -37.68% | 2M | -18.58% |
| New Positions | 22 | New | 722,962 | New |
| Sold Out Positions | 8 | Sold Out | 489,541 | Sold Out |
| Total Postitions | 99 | +43.48% | 12M | -5.57% |
| Omega Advisors Inc. | $25,929.00 | 6.29% | 3.27M | +2M | +98.17% | 2025-09-30 |
| Blackrock, Inc. | $13,308.00 | 3.23% | 1.68M | +486,326 | +40.81% | 2025-09-30 |
| Millennium Management Llc | $9,415.00 | 2.28% | 1.19M | +1M | New | 2025-09-30 |
| Paragon Associates & Paragon Associates Ii Joint Venture | $6,939.00 | 1.68% | 875,000 | +225,000 | +34.62% | 2025-09-30 |
| Geode Capital Management, Llc | $5,645.00 | 1.37% | 711,818 | +81,670 | +12.96% | 2025-09-30 |
| Vanguard Group Inc | $5,270.00 | 1.28% | 664,575 | -870,479 | -56.71% | 2025-09-30 |
| Morgan Stanley | $4,596.00 | 1.12% | 579,585 | +339,109 | +141.02% | 2025-09-30 |
| First Manhattan Co. Llc. | $4,005.00 | 0.97% | 505,000 | -101,435 | -16.73% | 2025-09-30 |
| State Street Corp | $3,779.00 | 0.92% | 476,583 | +224,635 | +89.16% | 2025-09-30 |
| Bleichroeder Lp | $3,032.00 | 0.74% | 382,317 | 0 | 0% | 2025-09-30 |